Ms. T, a patient from Mongolia, had active hepatitis D alongside chronic hepatitis B and advanced cirrhosis. With treatment options limited and the risk of progression requiring close specialist management, Harbor Health coordinated inpatient evaluation and treatment in Beijing.
An individualized plan led by liver-disease specialists
The supplied case material identifies Professor Wang Guiqiang as the lead expert. His team reviewed the HBV and HDV co-infection, liver reserve, cirrhosis status, and overall treatment tolerance before determining the care plan.
The plan centered on a China-developed neutralizing monoclonal antibody intended to block viral entry into liver cells, alongside specialist monitoring and longer-term management of chronic liver disease.
China’s newly approved antibody option for chronic hepatitis D
In January 2026, China’s National Medical Products Administration conditionally approved libevitug (HH-003) for adults with chronic hepatitis D, with or without compensated cirrhosis. The antibody targets the viral PreS1 region and blocks its interaction with the NTCP receptor, helping prevent HBV and HDV from entering hepatocytes.
The approved information describes intravenous infusion every two weeks, with the exact dose and treatment plan determined by an experienced clinician. This corrects the supplied English draft, which described the route as subcutaneous injection.
Clinical-study context and access support
The pivotal 48-week study reported group-level outcomes including a 44.1% combined response rate, a 60% virological response rate, and 70% ALT normalization. These trial results describe a study population and do not predict an individual patient’s response.
The case material states that Harbor Health also helped the patient apply to an official charitable medicine-assistance program, reducing the financial burden of longer-term treatment and follow-up.
Clinical note: The supplied case document does not name the antibody product. The regulatory and trial context above refers to libevitug (HH-003) because its mechanism, schedule, and data match the description; the patient’s exact product and regimen should be confirmed against the treating record. Individual outcomes vary.